Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism
- PMID: 26895319
- DOI: 10.1007/s11010-016-2669-2
Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism
Abstract
Oxidative stress has been implicated in the pathogenesis of hyperthyroidism and its complications. Interaction of advanced glycation end products (AGEs) with receptor RAGE (receptor for AGEs) generates reactive oxygen species. Soluble receptor for AGEs (sRAGE) competes with RAGE for binding with AGEs and attenuates the generation of ROS. Low levels sRAGE and high levels AGEs would generate more ROS leading to hyperthyroidism and its complications. The objectives are to determine if levels of serum sRAGE are low and the levels of AGEs and AGEs/sRAGE are high in patients with hyperthyroidism. The study subjects comprised of 33 patients with hyperthyroidism and 20 controls. Levels of serum sRAGE were lower, while that of AGEs and AGEs/sRAGE were higher in patients compared to controls, being significant only for sRAGE and AGEs/sRAGE. When the levels of sRAGE, AGEs, and AGEs/sRAGE were assessed for hyperthyroidism associated with different diseases, the levels of sRAGE were lower in Hashimoto disease, and levels of AGEs were higher in patients with Graves' disease compared to control. The levels of AGEs/sRAGE were elevated in an all except patients with Hashimoto disease. The levels of AGEs, sRAGE, or AGEs/RAGE were not correlated with age, weight, and blood pressures except systolic pressure which was inversely correlated with sRAGE. The levels of sRAGE were negatively correlated with AGEs and AGEs/sRAGE. The levels of AGEs/sRAGE were positively correlated with AGEs. In conclusion, low levels of sRAGE, and high levels of AGEs and AGEs/sRAGE are risk biomarkers in the pathogenesis hyperthyroidism and its complications.
Keywords: AGEs/sRAGE; Advanced glycation end products (AGEs); Hyperthyroidism; Pathogenesis; RAGE receptors; Reactive oxygen species; sRAGE.
Similar articles
-
Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?Mol Cell Biochem. 2019 Jan;451(1-2):139-144. doi: 10.1007/s11010-018-3400-2. Epub 2018 Jun 30. Mol Cell Biochem. 2019. PMID: 29961210 Review.
-
AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.Mol Cell Biochem. 2016 Dec;423(1-2):105-114. doi: 10.1007/s11010-016-2829-4. Epub 2016 Oct 6. Mol Cell Biochem. 2016. PMID: 27714575 Clinical Trial.
-
The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still's disease.BMC Musculoskelet Disord. 2015 May 9;16:111. doi: 10.1186/s12891-015-0569-3. BMC Musculoskelet Disord. 2015. PMID: 25956266 Free PMC article.
-
Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.Clin Interv Aging. 2014 Nov 19;9:1981-6. doi: 10.2147/CIA.S71130. eCollection 2014. Clin Interv Aging. 2014. PMID: 25429209 Free PMC article.
-
Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome.Biomed Res Int. 2015;2015:815942. doi: 10.1155/2015/815942. Epub 2015 Sep 30. Biomed Res Int. 2015. PMID: 26491690 Free PMC article. Review.
Cited by
-
Clinical characteristics and genetic analysis of a Chinese pedigree of type 2 diabetes complicated with interstitial lung disease.Front Endocrinol (Lausanne). 2023 Jan 17;13:1050200. doi: 10.3389/fendo.2022.1050200. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36733806 Free PMC article.
-
Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?Mol Cell Biochem. 2019 Jan;451(1-2):139-144. doi: 10.1007/s11010-018-3400-2. Epub 2018 Jun 30. Mol Cell Biochem. 2019. PMID: 29961210 Review.
-
Contribution of Glycation and Oxidative Stress to Thyroid Gland Pathology-A Pilot Study.Biomolecules. 2021 Apr 10;11(4):557. doi: 10.3390/biom11040557. Biomolecules. 2021. PMID: 33920190 Free PMC article.
-
The Role of Advanced Glycation End-Products in the Pathophysiology and Pharmacotherapy of Cardiovascular Disease.Int J Mol Sci. 2025 Jul 29;26(15):7311. doi: 10.3390/ijms26157311. Int J Mol Sci. 2025. PMID: 40806443 Free PMC article. Review.
-
Advanced glycation end products and their soluble receptor (sRAGE) in patients with Hashimoto's thyroiditis on levothyroxine substitution.Front Endocrinol (Lausanne). 2023 May 26;14:1187725. doi: 10.3389/fendo.2023.1187725. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37305044 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical